Introduction Thiopurine drugs are metabolised by a complex network of enzymes, each with individual genetic variability. Measurement of active metabolites, 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN), can have a role in optimising therapy for inflammatory bowel disease (IBD) patients.1
Aims/Background To evaluate how testing thiopurine metabolite(TPM) levels affects the management of patients with IBD receiving azathioprine or 6-mercaptopurine.
Method A retrospective laboratory database search for TPM levels. The results were analysed in conjunction with outpatient letters and concurrent laboratory data. The primary outcome: how had measuring TPM levels affected patient management? Secondary objective: to combine demographic and test result data to provide information on the patterns of thiopurine drug use in this population.
Results One hundred samples from 78 patients. 45% of samples led directly to changes in patient management. 15% led to dose escalation whilst 9% required dose reduction. The results of 8% led to the use of biological therapy. Treatment was stopped due to potential toxicity in 3%. In 8% of samples, patients were found to be poorly compliant with thiopurine treatment. 3 patients were completely non-compliant. In a sub-group of patients with low Thiopurine S-methyltransferase (TPMT), 78% had high levels of TGN despite the use of low drug doses.⇓ ⇓ ⇓
Conclusion Measuring TPMs is useful in the management of patients with IBD on thiopurines. They can reveal non-compliance and lead to dose alterations, treatment escalations and the prevention of drug toxicity. We would support the wider use of TPM testing in these patient groups.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.